Transposable elements in the keratinocyte genome and their regulation during skin development and epidermal differentiation
Project Number5R01AR078306-04
Contact PI/Project LeaderBOTCHKAREV, VLADIMIR A Other PIs
Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
PROJECT SUMMARY
In addition to signaling/transcription factor-dependent regulatory mechanisms, lineage-specific gene
expression programs in stem cells and their progenies are also regulated epigenetically, i.e., via regulation of
covalent DNA/histone modifications and higher-order chromatin remodeling. Epigenetic regulatory machinery
maintain the progenitor population and epithelial identity in epidermal keratinocytes, as well as inhibit premature
activation of terminal differentiation-associated genes and balance their transcription in differentiating cells.
Transposable elements (TEs) constitute a large portion (44%-55%) of the entire mouse or human
genomes. Most TEs are transcriptionally inactive under physiological conditions, while their inappropriate
activation has been implicated in pathogenesis of autoimmune disorders and carcinogenesis. In keratinocytes,
UV exposure activates transcription of various endogenous retroviral sequences which are closely related to the
sequences activated in lupus erythematosus patients. Furthermore, increasing evidence of data suggest an
involvement of endogenous TEs in the development of pro-inflammatory skin conditions, such as psoriasis.
However, there is a number of critical questions that this project seeks to investigate, remain unclear:
1) Which TEs are expressed in normal keratinocytes during skin development, postnatal homeostasis and
terminal differentiation, 2) Which mechanisms regulate TE silencing in keratinocytes, and 3) When TE silencing
is compromised, how are keratinocyte differentiation and epidermal inflammatory response impacted?
In this Multi-PI proposal, we will address the hypothesis that distinct classes of TEs differentially contribute
to the control of gene expression in epidermal keratinocytes, mediated by epigenetic regulators Lsh and Setdb1
that serve as critical determinants mediating the TE silencing and preventing pro-inflammatory responses in the
epidermis. This hypothesis will be addressed via three Specific Aims:
Aim 1. Define the landscape of transposable element expression in normal mouse and human
keratinocytes during skin development, postnatal homeostasis and terminal differentiation.
Aim 2. Define the roles for Lsh and Setdb1 in the control of transposable element silencing in
keratinocytes.
Aim 3. Define the impact and mechanisms associated with the transposable element activation in
keratinocytes on epidermal inflammatory response.
The generated outputs from this application will provide novel insights into fundamental mechanisms
underlying keratinocyte differentiation in normal mouse and human skin, as well as will promote the development
of novel paradigms for management of disorders of epidermal differentiation and inflammatory responses in
humans via modulation of TE activities.
Public Health Relevance Statement
PROJECT NARRATIVE
Transposable elements constitute a significant part of the non-coding genome, while their role in
epidermal development, homeostasis and keratinocyte differentiation remain to be elucidated. In
this proposal, we will address the following questions: 1) How are transposable elements
regulated in normal keratinocytes during development and terminal differentiation, 2) Which
mechanisms regulate their silencing in keratinocytes, and 3) When transposable element
silencing is compromised, how is epidermal development and homeostasis impacted. The
generated outputs on this project will provide a platform for their translation into clinics and will
promote the development of novel therapeutic interventions, which hopefully could serve as new
paradigm for management of skin inflammatory conditions and their prevention.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
16-March-2021
Project End Date
31-January-2026
Budget Start Date
01-February-2024
Budget End Date
31-January-2025
Project Funding Information for 2024
Total Funding
$465,640
Direct Costs
$282,206
Indirect Costs
$183,434
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$465,640
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AR078306-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AR078306-04
Patents
No Patents information available for 5R01AR078306-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AR078306-04
Clinical Studies
No Clinical Studies information available for 5R01AR078306-04
News and More
Related News Releases
No news release information available for 5R01AR078306-04
History
No Historical information available for 5R01AR078306-04
Similar Projects
No Similar Projects information available for 5R01AR078306-04